沃森生物(300142.SZ)子公司與蓋茨基金會簽署《沃森9價HPV疫苗開發資助協議》
格隆匯11月6日丨沃森生物(300142.SZ)公佈,近日,公司控股子公司上海澤潤生物科技有限公司(“上海澤潤”)與比爾及梅琳達·蓋茨基金會(“蓋茨基金會”)簽署了《沃森9價HPV疫苗開發資助協議》。
上海澤潤獲得了蓋茨基金會250萬美元的項目基金,用於加速重組人乳頭瘤病毒九價病毒樣顆粒疫苗(畢赤酵母)(“9價HPV疫苗”)的臨牀研究和產業化進度,並在此基礎上為世界衞生組織預認證(“WHO預認證”)做準備以供應國際組織大宗採購。
協議的主要內容如下:
1、項目基金主要將用於支持上海澤潤根據WHO預認證的要求,在9價HPV疫苗臨牀研究和產業化方面開展相關的工作;
2、上海澤潤應盡最大努力快速通過9價HPV疫苗的WHO預認證並承諾參加國際組織代表受援國家而進行的大宗採購招標;
3、上海澤潤承諾向國際組織援助的國家供應HPV疫苗,上海澤潤在定價政策和供貨量等方面也做出了相應的承諾。
協議的目的是支持上海澤潤研發安全、有效、低成本的9價HPV疫苗使其通過WHO預認證,將疫苗低價供應給國際組織資助的低收入國家,以改善其衞生狀況。
協議的簽署表明上海澤潤及其9價HPV疫苗項目得到了國際組織的認可,並奠定了上海澤潤在國際市場的發展方向。在9價HPV疫苗獲得WHO的預認證後,將進入國際組織大宗採購,為上海澤潤進入國際市場鋪平道路。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.